Company intelligence / Profile preview

Adwia

10th of Ramadan City, Egypt

Ownership: Private
Employees: ~1500
Development stage: Other

Overview

Adwia is a leading Egyptian pharmaceutical company that manufactures and markets a diverse portfolio of generic pharmaceutical products. The company covers a wide range of therapeutic areas including cardiovascular, gastrointestinal, and anti-infectives. In 2020, Adwia was acquired by a consortium led by SPE Capital, the European Bank for Reconstruction and Development (EBRD), and British International Investment (BII) to support its expansion in the Middle East and Africa.

Therapeutic areas: ImmunologyEndocrinologyCardiovascularNeurologyInfectious DiseasesGastroenterologyOphthalmology
Modalities: Small molecule
Industry: Biotech

Partnerships

EBRDSPE CapitalBritish International Investment

Beyond the preview

Go deeper on Adwia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adwia.

Explore the full profile